UPDATE 1-CSL says U.S. regulator may block Talecris deal

MELBOURNE, May 25 (Reuters) – U.S. Federal Trade Commission
officials are opposed to Australian biotech firm CSL Ltd’s
planned $3.1 billion purchase of smaller U.S. rival
Talecris Biotherapeutics Holdings Corp, CSL said on Monday.

Leave a Reply